Latest Stories

The Internet pioneer Marc Andreessen, co-creator of the web browser Mosaic and co-founder of Netscape, has a blog. It is well worth reading....

We're going through a periodic inflation scare. Basically, with central banks tightening (Europe) or standing firm (U.S.), and long-term interest...

The list of benefits doctors now attribute to breastfeeding is almost too good to be true. So why do so many hospitals send new mothers home with free baby formula? New York City and activist groups are out to stop the practice. Alisa Roth reports.

Call it a hedge fund with a conscience? Global Cool is using star power and rock concerts to spread its message on global warming — and making a return for its investors. In fact, it's a very serious investment fund, says Martin Waller.

It seems too good to be true — a device that can power lights, laptops, phones and just about anything else, through the air and without plugging in. But there are some drawbacks — Jill Barshay reports.

Cell phones that rely on Qualcomm chips to extend battery life were banned from U.S. import yesterday, but don't expect to see shipments piling up at the border. It's more likely to come down to deal-making, reports Janet Babin.

Yesterday in London, Virgin launched Europe's first passenger train using a blended fuel that reduces CO2 emissions. And Britain's soon-to-be prime minister Gordon Brown says tax breaks are ahead if the trial run is a success. Stephen Beard has more.

Fourteen states are protesting legislation in Congress they say will limit their efforts to cut greenhouse gas emissions. Automakers say it will be hard to comply if states start setting their own fuel-economy standards. Jeremy Hobson reports.

U.S. stock markets continued their plunge and investors spooked by inflation worries fled the bond market yesterday, sending prices tumbling. It all has a whole lot to do with central banks upping interest rates, Amy Scott reports.

Backers of stem-cell research say federal funding's needed, because wary investors won't step up to the plate. Investors worry that promising new therapies won't be profitable for years. Steve Tripoli reports.